Management of hepatocellular carcinomafrom diagnosis in routine clinical practice.

Abstract

To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 toMarch2019. Overall survivaland treatment journey were assessed over the entire available follow-up period per patient. Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72-82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy. This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.